Table 3 Adverse events in the safety data set (n = 501)

From: A randomized controlled trial on home blood pressure monitoring and quality of care in stage 2 and 3 hypertension

Adverse event

HBPM group (n = 96)

Control group (n = 405)

P

Dizziness

9 (9.4)

32 (7.9)

0.64

Hyperuricemia

7 (7.3)

18 (4.4)

0.37

Palpitation

2 (2.1)

3 (0.7)

0.25

Fatigue

2 (2.1)

2 (0.5)

0.17

Hypotension

2 (2.1)

1 (0.3)

0.10

Headache

1 (1.0)

6 (1.5)

0.99

Cough

1 (1.0)

2 (0.5)

0.47

Severe hypertension

0

5 (1.2)

0.59

Emesis

0

3 (0.7)

0.99

Other

13 (13.5)

53 (13.1)

0.91

Total

38 (39.6)

125 (30.9)

0.10

  1. Values are number of participants (% of column total), and listed in the descending order of the incidence rate in the HBPM group and then the control group. Adverse events were reported in this table either because the incidence rate exceeded 1% or because they were relevant for the study medication
Back to article page